Investor Relations
Breakthrough Oxygenation
Investment Highlights
Revolutionary early-stage extracorporeal respiratory support system designed to be administered while patients are awake and breathing spontaneously
Intended to use in non-invasive ventilation patients with acute respiratory failure to minimize the need for invasive mechanical ventilation
Initial pre-clinical studies (In-vivo) demonstrated the ART’s unique capabilities to rebalance
saturation levels in a significant manner³.
saturation levels in a significant manner³.
Indicators of growth in the market include the growing prevalence of chronic disorders, growing geriatric population, and the COVID-19 pandemic
3 strategic agreements for the deployment of the ART system in Europe and US. Agreement signed targets up to $386 million over a 7-year period, subject to regulatory approval.
Advisory board of leading professionals and experienced and committed management team
Technology Innovation Leadership award
Inspira Technologies earns Frost & Sullivan’s 2021 Technology Innovation Leadership Award with its innovative medical technology, the ART System, that aims to create a new standard of care in respiratory care industry
“Frost & Sullivan finds Inspira’s ART™ demonstrates the company’s excellence in innovation. The device overcomes the limitations of its predecessors to deliver a less-invasive respiratory support system, aligning with the company’s mission.”
Samantha Fisher, Best Practices Research Analyst
SEC Filings
Research Coverage
Bank
Analyst
Phone
E-mail
Aegis Capital
Nathan Weinstein, CFA
646-502-2522
nweinstein@aegiscap.com
These reports are prepared by independent analysts. Inspira does not endorse or distribute such reports and takes no responsibility for the accuracy or completeness of the material contained in the reports. Please note that any opinions, estimates or forecasts regarding the company’s performance made by these analysts are theirs alone and do not represent opinions, forecasts, or predictions of Inspira Technologies.
